Nucor earnings beat by $0.08, revenue fell short of estimates
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase 1 trial results for its INB-100 therapy. The company's stock has shown significant momentum recently, gaining over 24% in the past week. According to InvestingPro data, three analysts have revised their earnings estimates upward for the upcoming period. The data, presented at the 2025 Transplantation & Cellular Therapy Meetings, suggest that INB-100 could significantly reduce relapse in high-risk acute myeloid leukemia (AML) patients post-transplant.
The trial results indicated that none of the AML patients treated with INB-100 relapsed, with a median follow-up period of 20.1 months. Additionally, the 1-year progression-free survival rate was reported at 90.9%, with an overall survival rate of 100%. These outcomes surpass those of historical controls and suggest that INB-100 could potentially revolutionize post-transplant care in hematologic oncology.
IN8bio's CEO, William Ho, highlighted the durability of response and the favorable safety profile of INB-100, suggesting it could establish a new standard in managing leukemia after a transplant. Analyst confidence in the company's potential is reflected in price targets ranging from $1.50 to $8.00, according to InvestingPro data, though investors should note the company's current weak financial health score. Dr. Michael Bishop, a member of IN8bio's Scientific Advisory Board, echoed these sentiments, emphasizing the significance of the therapy's ability to maintain durable remission without the need for maintenance treatment.
The safety profile of INB-100 was also favorable, showing no instances of cytokine release syndrome, neurotoxicity, or treatment-related deaths. Evidence of in vivo expansion and long-term persistence of the gamma-delta T cells further reinforced the therapy's potential for sustained immune surveillance against residual leukemic cells.
IN8bio is moving forward with patient enrollment for the INB-100 program and anticipates completing the expansion cohort within 2025. The company has confirmed with the FDA that relapse-free survival is an acceptable primary endpoint for a potential future pivotal randomized controlled trial for AML patients.
With approximately 20,000 new AML cases and around 11,500 deaths annually in the U.S., the need for innovative treatments remains high. INB-100 utilizes the innate tumor-targeting properties of gamma-delta T cells, aiming to improve long-term outcomes for AML patients. Investors tracking IN8bio's progress should mark March 13, 2025, for the company's next earnings release. For deeper insights into IN8bio's financial health and additional ProTips, consider exploring InvestingPro, which offers comprehensive analysis tools and real-time market data.
These findings are based on a press release statement and are intended to offer a factual representation of IN8bio's reported data on INB-100 therapy.
In other recent news, IN8bio has been making significant strides in its clinical trials and has received positive feedback from analysts. The biotechnology firm's INB-100 treatment has shown promising outcomes in acute myeloid leukemia (AML) patients, with a 100% relapse-free survival rate at a median follow-up of 20.1 months. This favorable performance of INB-100 has led Jones Trading to upgrade IN8bio's stock rating to Buy from Hold, setting a new price target at $1.20.
In addition, IN8bio reported positive clinical data from a Phase 1 trial of INB-100, indicating that all AML patients treated with INB-100 post-hematopoietic stem cell transplantation remained in complete remission. This result outperforms historical control groups, further bolstering confidence in the effectiveness of IN8bio's treatment. H.C. Wainwright also maintained a positive outlook on IN8bio, reiterating a Buy rating and an $8.00 price target, following the presentation of clinical data from IN8bio's Phase 1 INB-200 study.
Moreover, IN8bio has been granted an additional 180 days to comply with Nasdaq's minimum bid price rule, according to a recent SEC filing. The company is considering strategies, including a potential reverse stock split, to address the bid price deficiency and regain compliance. These recent developments reflect IN8bio's ongoing progress and potential impact on the company's performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.